# Quetiapine Fumarate (SEROQUEL) Compared to Placebo in the Treatment of Children & Adolescents With Bipolar I Mania

> **NCT00090311** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 220 (actual)

## Conditions studied

- Bipolar Disorder

## Interventions

- **DRUG:** quetiapine fumarate

## Key facts

- **NCT ID:** NCT00090311
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-07
- **Primary completion:** —
- **Final completion:** 2006-07
- **Target enrollment:** 220 (ACTUAL)
- **Last updated:** 2013-01-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00090311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00090311, "Quetiapine Fumarate (SEROQUEL) Compared to Placebo in the Treatment of Children & Adolescents With Bipolar I Mania". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00090311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*